University of Alabama at Birmingham

O'Neal Comprehensive Cancer Center

Birmingham, AL

Accepting patients

CA057-003

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Phase 1/2

Accepting patients

Alnuctamab

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more
  • Bispecific Antibody
  • CAR T Cell
  • CELMoD
  • BCMA
  • GPRC5D
  • Phase 1

Accepting patients

Alnuctamab With Mezigdomide

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • CELMoD
  • BCMA
  • Phase 1/2
2 hidden based on your filters. Show All

Filters

Diagnosis

Treatment History

Prior BCMA Therapy

Advanced Filters

Classifications

Trial Enrollment Status